PORTIA-21 Drug Patent Profile
✉ Email this page to a colleague
When do Portia-21 patents expire, and what generic alternatives are available?
Portia-21 is a drug marketed by Barr and is included in one NDA.
The generic ingredient in PORTIA-21 is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PORTIA-21?
- What are the global sales for PORTIA-21?
- What is Average Wholesale Price for PORTIA-21?
Summary for PORTIA-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 7 |
| Patent Applications: | 277 |
| DailyMed Link: | PORTIA-21 at DailyMed |
Recent Clinical Trials for PORTIA-21
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| ViiV Healthcare | Phase 1 |
| Pfizer | Phase 1 |
| Memorial Sloan Kettering Cancer Center | Phase 1 |
US Patents and Regulatory Information for PORTIA-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | PORTIA-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 075866-001 | May 23, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
